A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

NCT ID: NCT04171765

Last Updated: 2024-04-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-30

Study Completion Date

2023-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants will receive a fixed dose of placebo matched to BFKB8488A.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.

Fixed Dose: BFKB8488A Dose A

Participants will receive BFKB8488A.

Group Type EXPERIMENTAL

BFKB8488A

Intervention Type DRUG

Participants will receive subcutaneous (SC) BFKB8488A.

Fixed Dose: BFKB8488A Dose B

Participants will receive BFKB8488A.

Group Type EXPERIMENTAL

BFKB8488A

Intervention Type DRUG

Participants will receive subcutaneous (SC) BFKB8488A.

Fixed Dose: BFKB8488A Dose C

Participants will receive BFKB8488A.

Group Type EXPERIMENTAL

BFKB8488A

Intervention Type DRUG

Participants will receive subcutaneous (SC) BFKB8488A.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.

Intervention Type DRUG

BFKB8488A

Participants will receive subcutaneous (SC) BFKB8488A.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of NASH as documented through liver biopsy performed no more than 6 months before randomization, defined according to NASH CRN criteria along with a NASH CRN fibrosis score between F2 and F3
* Hepatic steatosis on MRI (\>= 8% average PDFF) prior to randomization

Exclusion Criteria

* History of any liver disease other than NASH, except for resolved, self-limited illnesses such as Hepatitis A or E, and previous Hepatitis C
* Weight gain \> 10% or loss \> 5% within 3 months prior to randomization
* History of liver transplantation
* Current or history of significant alcohol consumption
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cullman Clinical Trials

Cullman, Alabama, United States

Site Status

Arizona Liver Health - Chandler

Chandler, Arizona, United States

Site Status

Arizona Liver Health - Tucson

Tucson, Arizona, United States

Site Status

Orange Grove Family Practice

Tucson, Arizona, United States

Site Status

Arkansas Gastroenterology

North Little Rock, Arkansas, United States

Site Status

Gregory Wiener, MD

Chula Vista, California, United States

Site Status

Community Cancer Institute (CCI)

Fresno, California, United States

Site Status

National Research Inst.

Los Angeles, California, United States

Site Status

Conquest Clinical Research

Orange, California, United States

Site Status

UC San Diego Airway Research and Clinical Trials Center

San Diego, California, United States

Site Status

National Research Institute - Panorama City

Santa Monica, California, United States

Site Status

South Denver Gastroenterology

Englewood, Colorado, United States

Site Status

Excel Medical Research

Boca Raton, Florida, United States

Site Status

Premier Research Associate, Inc

Miami, Florida, United States

Site Status

Covenant Research

Sarasota, Florida, United States

Site Status

Gastrointestinal Specialists of Georgia, PC

Marietta, Georgia, United States

Site Status

Grand Teton Research Group, PLLC

Idaho Falls, Idaho, United States

Site Status

Gastroenterology Associates, LLC

Baton Rouge, Louisiana, United States

Site Status

Avant Research Associates, LLC

Crowley, Louisiana, United States

Site Status

Walter Reed Army Medical Center

Bethesda, Maryland, United States

Site Status

Huron Gastroenterology Associates

Ypsilanti, Michigan, United States

Site Status

Kansas City Research Institute, LLC

Kansas City, Missouri, United States

Site Status

Amici Clinical Research

Raritan, New Jersey, United States

Site Status

Duke Medical Center; Gen Clinic Research Ctr

Durham, North Carolina, United States

Site Status

Wexner Medical Center; Ohio State University; Investigational Drug Services; Pharmacy Department

Columbus, Ohio, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Pinnacle Clinical Research - Austin

Austin, Texas, United States

Site Status

Texas Digetive Disease Consultants - Austin

Cedar Park, Texas, United States

Site Status

Liver Institute at Renaissance

Edinburg, Texas, United States

Site Status

South Texas Research Institute

Edinburg, Texas, United States

Site Status

Texas Digestive Disease Consultant - Ft Worth (TDDC - Ft Worth)

Fort Worth, Texas, United States

Site Status

Liver Associates of Texas - Houston

Houston, Texas, United States

Site Status

Quality Research Inc

San Antonio, Texas, United States

Site Status

American Research Corporation Inc.

San Antonio, Texas, United States

Site Status

Clinical Trials of Texas, Inc

San Antonio, Texas, United States

Site Status

Pinnacle Clinical Research - San Antonio

San Antonio, Texas, United States

Site Status

Texas Digestive Disease Consultants - San Marcos

San Marcos, Texas, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Hunter Holmes McGuire V.A. Medical Center

Richmond, Virginia, United States

Site Status

Hospital Erasme

Brussels, , Belgium

Site Status

Antwerp University Hospital

Edegem, , Belgium

Site Status

Universitair Ziekenhuis Gent

Ghent, , Belgium

Site Status

CHU Hopitaux de Bordeaux

CHU Hopitaux de Bordeaux, , France

Site Status

Hospices Civils de Lyon

Lyon, , France

Site Status

CHU de Nice

Nice, , France

Site Status

Hopital Pitie-Salpetriere APHP

Paris, , France

Site Status

Hôpital d'Enfants, Service d?onco-hématologie pédiatrique

Vandœuvre-lès-Nancy, , France

Site Status

Fundacion de Investigacion de Diego

San Juan, , Puerto Rico

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universtiario Virgen del Rocio

Seville, , Spain

Site Status

Hospital Clinico Universitario de Valencia; Servicio de Anatomia Patologica

Valencia, , Spain

Site Status

Consorcio Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Hospital Universitari i Politecnic La Fe; Servicio de Neurología

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium France Puerto Rico Spain

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GC41033

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.